Announcements

7 August 2024
MDPI Insights: The CEO's Letter #14 - New Headquarters, Marketing, Poland

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI Moves to New Headquarters in Basel, Switzerland

I am excited to share that MDPI has moved to a new state-of-the-art office space in Basel, Switzerland. This move consolidates our operations by bringing together our two previously separated Basel offices into one central location.

We are always growing our talent pool and encourage you to view our Careers Page for the positions available in Basel and across our offices.

New Address: Grosspeteranlage 5, CH-4052 Basel, Switzerland

Effective Date: 1 July 2024

This new chapter in our company’s journey is designed to continue our mission of positioning MDPI as a leader in Open Access (OA) publishing, highlighting our commitment to making scholarly research accessible to everyone.

Boasting modern amenities, improved meeting and event spaces designed to support our growing needs, the new location provides a more collaborative and efficient working environment for our employees. The location offers convenient accessibility to public transportation and is situated near the Basel SBB railway station, with a variety of nearby services and amenities.

In fact, I can see the trains right outside of my window as I write these lines!

This move marks an exciting milestone in MDPI’s development, and I am confident that the new headquarters will serve as an inspiring and productive space for everyone. We also very much look forward to welcoming visitors here. You can read more about MDPI's history here.

“This new chapter continues our mission of positioning MDPI as a leader in OA publishing”

For Those New to MDPI

A pioneer in scholarly, Open Access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to Open Science by making a greater proportion of the research conducted worldwide free and accessible to everyone. To date, over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6,000 professional, well-trained staff members, and an in-house article submission platform designed to ensure efficient processes within its 440 fully Open Access titles. MDPI supports more than 800 academic institutions worldwide, helping them adhere to national mandates while facilitating authors’ publication in fully compliant (CC BY) Open Access journals.

Impactful Research

New and Emerging MDPI Journals Making an Immediate Impact

Unpacking some of the Impact Factor updates from the June CEO Letter, I wanted to dive a little deeper into the 137 MDPI journals which received Impact Factor for the first time.

Academic authors highly value efficient publishing processes, robust editorial support, and the opportunity to publish in high-impact journals. We are proud that our newly launched journals typically achieve coverage in the Emerging Sources Citation Index (ESCI) of the Web of Science within just a few years, with a median time of only three years from release to inclusion.

As part of our commitment to advancing academic research and providing high-quality OA publishing, we actively seek new research areas to expand our portfolio of journals. We have a proven track record of successfully establishing new journals.

Our dedicated teams excel in fostering dynamic editorial boards and working closely with Editors-in-Chief (EiC) to define the precise scope and focus of each new journal. Our expertise extends to collaborating with indexing services, ensuring that our journals comply with best practices and are indexed promptly in all relevant databases.

Emerging Titles Ranked for the First Time

Our commitment to excellence is reflected in the annual impact metrics released this past June. The latest edition of the Journal Citation Reports (JCR) showcases the integration of journals from the ESCI in the new unified category rankings, providing a simplified and more complete view of all journals within each subject category, including newly established titles.

Out of 137 new and developing MDPI journals ranked in the 2024 release, 79 are in the top half (Q1 or Q2) of their categories. Here is a breakdown of the number of MDPI’s ESCI-indexed journals by quartile in the JCR:

Quartile No. of journals
Q1 17 (12.4%)
Q2 62 (45.3%)
Q3 43 (31.4%)
Q4 15 (10.9%)
Not ranked (humanities-related journals) 2

These rankings highlight our success in rapidly establishing high-impact new journals. Among those that made it directly into the top 25% of their category are the International Journal of Neonatal Screening, Journal of Xenobiotics, Polysaccharides, Smart Cities, and thirteen other journals.

You can browse MDPI journals by Indexing. Simply visit our Journals page and select from the list of Indexing bodies in the top left-hand corner.

For quick reference, as at 31 July 2024:

Inside MDPI

MDPI Corporate Marketing Strategy and Team Meeting 2024

In July, I hosted the annual Corporate Marketing strategy and team-building activity with 15 of our team members.

The aim was to align the Corporate Marketing strategy with MDPI's goal of becoming the world's most trusted OA publisher. While we provide a high-level publishing experience for our authors, as seen from our surveys, we need to keep building on our transparent and open communication to foster trust within the scholarly community and continue enhancing our reputation.

The Corporate Marketing team plays an important role as the mouthpiece for all our major activities within MDPI, especially those that model what it means to be a trusted partner. The purpose of the strategy meeting was to develop a feeling of trust in one another and an understanding of how to inspire trust in the stakeholders with whom we interact.

“We need to keep building on our transparent and open communication to foster trust within the scholarly community”

We conducted a set of activities to facilitate that sense of mutual trust and trustworthiness. Examples of some activities we worked on during this strategy-building event include:

  • Exploring what trust means
    • ‘Letter to self’
    • ‘The brand I most trust’
  • Most Trusted Academic Publisher
    • ‘The brand I would like MDPI to become’
    • ‘The 2029 MDPI Annual Report’
    • Voice of Customer and Share of Voice – survey/data update on MDPI Brand Experience and Brand Perception
  • Integrate Trust-Based Objective into Marketing Plan
    • ‘Becoming the MDPI experience’
    • ‘Trusting the next steps’

While two days is not enough to finalize a marketing strategy, it is sufficient to get everyone who attended into the mindset of the direction in which we are working. From here, we will develop a program with next steps on main projects, update communications, and collaborate with team leads to incorporate this approach into our work going forward.

As a marketing team, we can communicate our messages, but trust has to be built at every touchpoint in the stakeholder journey. Just talking about it isn’t enough. We need to be about it. That’s a role each of us plays, from editorial to IT, from marketing to HR. We must build trust from the inside out. It starts with each manager and resonates out via every team member.

As a company, our goal is to give all stakeholders with whom we interact – whether internal or external – the experience of working with an organization it can trust.

Coming Together for Science

MDPI in Poland: Krakow Office

In July, I had the pleasure of visiting our Krakow office, following my recent trip to Warsaw to meet with the Polish Ministry of Science and Higher Education.

During these visits, I prioritized meeting with our Office Manager, Editorial Director, Group Leads, and members from various teams, including editorial, production, marketing, and journal relationship specialists, to understand their roles and current challenges. Instead of a formal presentation, I opted for an open discussion, sharing updates from headquarters to engage with colleagues in a more personal way.

Our Krakow office has many things to be proud of, including a large number of PhD colleagues (over a third of its staff holds a PhD degree). Krakow provides an opportunity for expanding beyond the 100 colleagues we currently have, by adding new hires in departments including editorial, production and marketing, among others.

About our Krakow office

  • Opened in 2020
  • 99 staff members as at 1 August 2024
  • Main Departments include Editorial, Production, English Department, JRS, PR

Our Krakow office participates in international conferences, conducts author trainings and scholar visits, and engages in local market outreach. The office is also a member of the Polish Chamber of Commerce for High Technology (IZTECH) and is working on expanding its local engagement.

Krakow is the second-largest city in Poland, with a population of about 800,000. It also has a large student population of around 128,000, with seven universities. This means that roughly one in every eight residents is a student.

Poland and MDPI

Poland is a crucial market for MDPI. From 2020 to June 2024, Poland ranked 7th in submissions and 5th in publications for MDPI research articles. As at 31 July 2024, Poland ranks 7th in total MDPI publications, with approximately 70,000 research papers.

Between 2020 and June 2024, 61,500 authors from Poland published with MDPI. As at 30 June 2024, there are 1,205 active Editorial Board Members (EBMs) from Poland, with 661 EBMs (55% of the total) having an H-index over 25.

We also have four Editors-in-Chief (EiC) from Poland leading our journals: Coatings, Venereology, Advances in Respiratory Medicine, and Limnological Review, along with six Section EiC.

In 2023, we received approximately 21,000 submissions from Polish-affiliated authors, of which 12,032 were published.

“Poland is a crucial market for MDPI”

Meeting with Ministry of Education

On 22 July, we visited Warsaw to meet with the Polish Ministry of Science and Higher Education.

We were pleased to learn that they are strong supporters of the OA publishing model and value MDPI’s approach to the peer-review process, including our high ethical standards for quality control.

In 2023 Polish authors predominantly published their papers in OA, with MDPI holding the largest market share in OA publications within the country.

Our commitment to collaborating with Polish institutions is evident through our 33 Institutional Open Access Program (IOAP) agreements with prestigious institutions such as the University of Warsaw, the University of Wroclaw, the Jagiellonian University, and Gdańsk University of Technology. Through IOAP discounts, a healthy waiver rate, and our peer-review voucher system, we provide the Polish scholarly community with significant savings in OA publishing. The Minister greatly appreciated these efforts and our commitment to offsetting some of the APC costs.

We discussed industry concerns about the threat of papermills and presented the preventive measures MDPI has in place to mitigate this risk and uphold high ethical standards. We informed them of our commitment to combating papermills, including our involvement with United2Act and the STM Research Integrity Hub, as well as our efforts to expand our research integrity team and explore proactive measures.

Closing Thoughts

MDPI Thought Leadership Op-ed on Open Access is Now Live on Politico

I am pleased to share that our thought leadership Op-ed piece on Open Access (OA) is now live on Politico. This is a nice push for continued influence and support of OA among policymakers and industry leaders.

Why Politico?

Politico's reputation as a highly credible and influential news platform makes it an important venue to reach key opinion leaders (KOL) from academia, policymakers, and thought leaders from many industries. This visibility helps promote the OA philosophy.

Open Access: A Moral Imperative for Progress

In this piece, I discuss the necessity of making scientific research freely available to all. I argue that publicly funded research should be publicly accessible, highlighting how OA democratizes scientific knowledge, accelerates research availability, and fosters collaboration.

“Open Access is a fundamental right for all citizens”

Democratizing scientific communication
The impulse to democratize scientific communication is nothing new. OA may seem like a recent innovation, but its principles have historical roots traceable to Europe in the 15th century. Just as the printing revolution accelerated the dissemination of new ideas, OA publishing unlocks new scientific insights that would otherwise only be accessible to a few.

Benefits for scholars: amplifying impact through Open Access
Authors publishing in an OA journal can expect more citations of their work, increasing its potential impact. Research findings that are freely available are more likely to be cited than those hidden behind a paywall. Freedom of access greatly increases the potential audience for each paper, fostering a sense of community among researchers worldwide. Heightened visibility can attract prospective collaborators and employers for young scientists. At MDPI, we believe that all these factors can only accelerate the advance of science. Additionally, authors retain copyright in their work instead of signing it away, permitting broader dissemination under Creative Commons licenses and increasing its capacity for impact.

The moral imperative
OA is not just a matter of scientific policy; it is a fundamental right for all citizens and a prerequisite for a brighter, more informed future. Publicly funded research should be a top priority, and I am pleased to see policy moving in this direction. Our capacity to generate transformative scientific insights has to be democratized. The question today is no longer whether we can afford to embrace OA; rather, it is whether we can afford not to.

Stefan Tochev
Chief Executive Officer
MDPI AG

2 August 2024
MDPI Romania Author Training Sessions in May

In May, MDPI Romania held three author training sessions – one endorsing an external event and two stand-alone sessions.

The National Session of Scientific Student Communications took place at Technical University Cluj on 17 and 18 May 2024. MDPI Romania sponsored this event and contributed an author training session on the production of research papers and case study analyses. JRS Norbert Kiss gave a presentation called The World of Open Access to explain different open access publishing models and the benefits of open access publishing. His presentation highlighted the impact of open access publishing on scientific progress and innovation.

On 29 May 2024, MDPI Romania hosted an author training session for Ph.D. students, early career researchers, and professors at the Carol Davila University of Medicine and Pharmacy. In collaboration with Prof. Andreea Arsene, JRS Ioana Paunescu prepared two presentations: The Steps of the Publishing Process and Elaboration of a Peer Review Report. In her first presentation, she delved into MDPI’s history and mission, MDPI’s editorial process, and MDPI journals of various scopes that are accepting submissions. Her second presentation outlined the types of peer review, the contents of a peer review report by an MDPI reviewer, and the responsibilities of an MDPI reviewer.

MDPI Romania also hosted an author training session at the Iasi University of Life Sciences on 29 May 2024. JRSs Laurentiu Preda and Cosmin Artan gave four presentations: Efficient Writing of an ISI-Indexed Scientific Article, Benefits of Publishing in the Open Access Model, Various Methods of Open Access Publishing, and MDPI Guide for the Article Review Process. The first three presentations offered guidance on how to improve academic writing, the fourth focused on how to write peer review reports. A highly interactive discussion followed the presentations, during which the JRSs provided extensive answers to attendees’ questions.

MDPI is grateful for all the attendees, speakers, and organizers involved in these events. Through their enthusiasm and dedication, these events were great successes.

1 August 2024
Meet Us at the 2024 CAMO Annual Scientific Meeting, 24–26 October 2024, Ottawa, ON, Canada


Conference: 2024 CAMO Annual Scientific Meeting

Date: 24–26 October 2024

Location: Ottawa, ON, Canada

The Canadian Association of Medical Oncologists (CAMO) is a national specialty society of the Royal College of Physicians and Surgeons of Canada. Their mission is to contribute to cancer control, through research, education, and clinical practice in prevention, screening, diagnosis, treatment, supportive care, palliative care, and rehabilitation. The Association is committed to achieving and maintaining, among its members, excellence in clinical and scholarly activity, within a culture of compassion and respect for human dignity. CAMO Annual Scientific Meetings have been held since 2014.

The following MDPI journals will be represented at the 2024 CAMO Annual Scientific Meeting:

Our delegates look forward to meeting you in person at the booth at the conference and answering any questions you may have. For more information regarding the conference, please visit the following link: https://camo-acom.ca/page-1549450.

26 July 2024
Meet Us at the 22nd Congress of the International Society for Burn Injuries (ISBI) and the 55th Annual Meeting of the British Burn Association (BBA), 18–22 August 2024, Birmingham, UK


MDPI will be attending the 22nd Congress of the International Society for Burn Injuries (ISBI) and the 55th Annual Meeting of the British Burn Association (BBA) in Birmingham, UK, from 18 to 22 August 2024. The 2024 ISBI/BBA Congress is organized to continue to promote the concept of “one world and one standard of burn care” for people suffering as a result of a thermal injury.

The following MDPI journals will be represented:

If you are planning to attend the conference, please do visit our booth. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit the following website: https://worldburn.org/events/7/2024_isbibba_congress.

24 July 2024
Journal of Personalized Medicine | Top 10 Cited Papers on Liver Disease in 2022–2023


28 July 2024 marks the 14th World Hepatitis Awareness Day, with various global events taking place to promote this important date. The aim of this day is to make more people aware of the dangers of hepatitis and draw their attention to this condition.

We would like to take this opportunity to extend our appreciation to all researchers who have contributed to the fight against hepatitis. In particular, we would like to share some of the high-quality and innovative research findings in the field of personalized therapy for hepatitis and liver disease, published in the Journal of Personalized Medicine (JPM, ISSN: 2075-4426).

We hope that this announcement will provide useful information on research in this evolving field.

The list of relevant papers can be seen below:

1. “Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice”
by Federica Invernizzi, Marta Cilla, Silvia Trapani, Maria Guarino, Valentina Cossiga, Martina Gambato, Maria Cristina Morelli, Filomena Morisco, Patrizia Burra and Annarosa Floreani
J. Pers. Med. 2022, 12(6), 925; https://doi.org/10.3390/jpm12060925
Available online: https://www.mdpi.com/2075-4426/12/6/925
Cited by 14+ | Viewed by 2830+

2. “Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma”
by Chun-Wei Huang, Tsung-Han Wu, Heng-Yuan Hsu, Kuang-Tse Pan, Chao-Wei Lee, Sio-Wai Chong, Song-Fong Huang, Sey-En Lin, Ming-Chin Yu and Shen-Ming Chen
J. Pers. Med. 2022, 12(4), 518; https://doi.org/10.3390/jpm12040518
Available online: https://www.mdpi.com/2075-4426/12/4/518
Cited by 12+ | Viewed by 3675+

3. “Efficacy and Safety of Distal Radial Access for Transcatheter Arterial Chemoembolization (TACE) of the Liver”
by Roberto Minici, Raffaele Serra, Marco Giurdanella, Marisa Talarico, Maria Anna Siciliano, Gianpaolo Carrafiello and Domenico Laganà
J. Pers. Med. 2023, 13(4), 640; https://doi.org/10.3390/jpm13040640
Available online: https://www.mdpi.com/2075-4426/13/4/640
Cited by 12+ | Viewed by 3130+

4. “Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease”
by Laura Valenzuela-Vallejo, Despina Sanoudou and Christos S. Mantzoros
J. Pers. Med. 2023, 13(5), 830; https://doi.org/10.3390/jpm13050830
Available online: https://www.mdpi.com/2075-4426/13/5/830
Cited by 10+ | Viewed by 2625+

5. “Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis”
by JiHyun An, Dong Ah Park, Min Jung Ko, Sang Bong Ahn, Jeong-Ju Yoo, Dae Won Jun and Sun Young Yim
J. Pers. Med. 2022, 12(9), 1517; https://doi.org/10.3390/jpm12091517
Available online: https://www.mdpi.com/2075-4426/12/9/1517
Cited by 9+ | Viewed by 1875+

6. “Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression”
by Mathias Jachs, Lukas Hartl, David Bauer, Benedikt Simbrunner, Albert Friedrich Stättermayer, Robert Strassl, Michael Trauner, Mattias Mandorfer and Thomas Reiberger
J. Pers. Med. 2022, 12(2), 239; https://doi.org/10.3390/jpm12020239
Available online: https://www.mdpi.com/2075-4426/12/2/239
Cited by 7+ | Viewed by 2130+

7. “Cytokines and Hepatocellular Carcinoma: Biomarkers of a Deadly Embrace”
by Krizia Pocino, Annunziata Stefanile, Valerio Basile, Cecilia Napodano, Francesca D’Ambrosio, Riccardo Di Santo, Cinzia Anna Maria Callà, Francesca Gulli, Raffaele Saporito, Gabriele Ciasca et al.
J. Pers. Med. 2023, 13(1), 5; https://doi.org/10.3390/jpm13010005
Available online: https://www.mdpi.com/2075-4426/13/1/5
Cited by 7+ | Viewed by 2290+

8. “Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia”
by Rita Moretti, Mauro Giuffré, Lory Saveria Crocè, Silvia Gazzin and Claudio Tiribelli
J. Pers. Med. 2022, 12(7), 1106; https://doi.org/10.3390/jpm12071106
Available online: https://www.mdpi.com/2075-4426/12/7/1106
Cited by 7+ | Viewed by 2060+

9. “Clinical and Genetic Risk Factors for Drug-Induced Liver Injury Associated with Anti-Tuberculosis Treatment—A Study from Patients of Portuguese Health Centers”
by Maria João Cavaco, Celeste Alcobia, Bárbara Oliveiros, Luís Alcides Mesquita, Aurora Carvalho, Fernando Matos, José Miguel Carvalho, Miguel Villar, Raquel Duarte, João Mendes et al.
J. Pers. Med. 2022, 12(5), 790; https://doi.org/10.3390/jpm12050790
Available online: https://www.mdpi.com/2075-4426/12/5/790
Cited by 7+ | Viewed by 3720+

10. “Impact of l-Carnitine Supplementation on Liver Enzyme Normalization in Patients with Chronic Liver Disease: A Meta-Analysis of Randomized Trials”
by Hyunwoo Oh, Chan Hyuk Park and Dae Won Jun
J. Pers. Med. 2022, 12(7), 1053; https://doi.org/10.3390/jpm12071053
Available online: https://www.mdpi.com/2075-4426/12/7/1053
Cited by 7+ | Viewed by 2200+

To read more relevant papers, subscribe to JPM at https://www.mdpi.com/journal/jpm/toc-alert.

JPM Editorial Office

24 July 2024
Journal of Personalized Medicine | Highly Cited Papers in 2022–2023 in the Section “Clinical Medicine, Cell, and Organism Physiology”


We are pleased to invite you to read the highly cited papers in 2022 and 2023 in the Journal of Personalized Medicine (JPM, ISSN: 2075-4426) in the Section “Clinical Medicine, Cell, and Organism Physiology”. The list of papers is as follows:

1. “CD24: A Novel Target for Cancer Immunotherapy”
by Emmanouil Panagiotou, Nikolaos K. Syrigos, Andriani Charpidou, Elias Kotteas and Ioannis A. Vathiotis
J. Pers. Med. 2022, 12(8), 1235; https://doi.org/10.3390/jpm12081235
Available online: https://www.mdpi.com/2075-4426/12/8/1235
Cited by 34+ | Viewed by 6195+

2. “Pericapsular Nerve Group (PENG) Block versus Supra-Inguinal Fascia Iliaca Compartment Block for Total Hip Arthroplasty: A Randomized Clinical Trial”
by Yong Seon Choi, Kwan Kyu Park, Bora Lee, Won Seok Nam and Do-Hyeong Kim
J. Pers. Med. 2022, 12(3), 408; https://doi.org/10.3390/jpm12030408
Available online: https://www.mdpi.com/2075-4426/12/3/408
Cited by 33+ | Viewed by 9925+

3. “Combination Therapies for Nonalcoholic Fatty Liver Disease”
by Evangelia S. Makri, Eleftheria Makri and Stergios A. Polyzos
J. Pers. Med. 2022, 12(7), 1166; https://doi.org/10.3390/jpm12071166
Available online: https://www.mdpi.com/2075-4426/12/7/1166
Cited by 22+ | Viewed by 3375+

4. “Adipose-Derived Stem Cells for Facial Rejuvenation”
by Agnieszka Surowiecka and Jerzy Strużyna
J. Pers. Med. 2022, 12(1), 117; https://doi.org/10.3390/jpm12010117
Available online: https://www.mdpi.com/2075-4426/12/1/117
Cited by 21+ | Viewed by 7365+

5. “Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study”
by Stefania Gallo, Paolo Castelnuovo, Luca Spirito, Marta Feduzi, Veronica Seccia, Dina Visca, Antonio Spanevello, Erica Statuti, Manuela Latorre, Claudio Montuori et al.
J. Pers. Med. 2022, 12(8), 1304; https://doi.org/10.3390/jpm12081304
Available online: https://www.mdpi.com/2075-4426/12/8/1304
Cited by 19+ | Viewed by 3060+

6. “A Revised Stem Cell Theory for the Pathogenesis of Endometriosis”
by Tetsuo Maruyama
J. Pers. Med. 2022, 12(2), 216; https://doi.org/10.3390/jpm12020216
Available online: https://www.mdpi.com/2075-4426/12/2/216
Cited by 18+ | Viewed by 5895+

7. “Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement”
by Eugenio De Corso, Maria Beatrice Bilò, Andrea Matucci, Veronica Seccia, Fulvio Braido, Matteo Gelardi, Enrico Heffler, Manuela Latorre, Luca Malvezzi, Girolamo Pelaia et al.
J. Pers. Med. 2022, 12(5), 846; https://doi.org/10.3390/jpm12050846
Available online: https://www.mdpi.com/2075-4426/12/5/846
Cited by 16+ | Viewed by 4375+

8. “Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach”
by Veronica Seccia, Maria D’Amato, Giulia Scioscia, Diego Bagnasco, Fabiano Di Marco, Gianluca Fadda, Francesco Menzella, Ernesto Pasquini, Girolamo Pelaia, Eugenio Tremante et al.
J. Pers. Med. 2022, 12(7), 1096; https://doi.org/10.3390/jpm12071096
Available online: https://www.mdpi.com/2075-4426/12/7/1096
Cited by 15+ | Viewed by 3870+

9. “Use of High-Frequency Transducers in Breast Sonography”
by Antonio Corvino, Carlo Varelli, Fabio Catalano, Giulio Cocco, Andrea Delli Pizzi, Andrea Boccatonda, Fabio Corvino, Luigi Basile and Orlando Catalano
J. Pers. Med. 2022, 12(12), 1960; https://doi.org/10.3390/jpm12121960
Available online: https://www.mdpi.com/2075-4426/12/12/1960
Cited by 15+ | Viewed by 2930+

10. “Personalized Self-Monitoring of Energy Balance through Integration in a Web-Application of Dietary, Anthropometric, and Physical Activity Data”
by Giada Bianchetti, Alessio Abeltino, Cassandra Serantoni, Federico Ardito, Daniele Malta, Marco De Spirito and Giuseppe Maulucci
J. Pers. Med. 2022, 12(4), 568; https://doi.org/10.3390/jpm12040568
Available online: https://www.mdpi.com/2075-4426/12/4/568
Cited by 13+ | Viewed by 2635+

11. “Prevention of Post-Transplant Diabetes Mellitus: Towards a Personalized Approach”
by Didier Ducloux and Cécile Courivaud
J. Pers. Med. 2022, 12(1), 116; https://doi.org/10.3390/jpm12010116
Available online: https://www.mdpi.com/2075-4426/12/1/116
Cited by 12+ | Viewed by 2670+

12. “Epidemiology and Risk Factors of UTIs in Children—A Single-Center Observation”
by Maria Daniel, Hanna Szymanik-Grzelak, Janusz Sierdziński, Edyta Podsiadły, Magdalena Kowalewska-Młot and Małgorzata Pańczyk-Tomaszewska
J. Pers. Med. 2023, 13(1), 138; https://doi.org/10.3390/jpm13010138
Available online: https://www.mdpi.com/2075-4426/13/1/138
Cited by 12+ | Viewed by 3770+

13. “The Role of BDNF as a Biomarker in Cognitive and Sensory Neurodegeneration”
by Anna Pisani, Fabiola Paciello, Valeria Del Vecchio, Rita Malesci, Eugenio De Corso, Elena Cantone and Anna Rita Fetoni
J. Pers. Med. 2023, 13(4), 652; https://doi.org/10.3390/jpm13040652
Available online: https://www.mdpi.com/2075-4426/13/4/652
Cited by 12+ | Viewed by 3395+

14. “Sinonasal Biomarkers Defining Type 2-High and Type 2-Low Inflammation in Chronic Rhinosinusitis with Nasal Polyps”
 by Eugenio De Corso, Silvia Baroni, Stefano Settimi, Maria Elisabetta Onori, Rodolfo Francesco Mastrapasqua, Eliana Troiani, Giacomo Moretti, Donatella Lucchetti, Marco Corbò, Claudio Montuori et al.
J. Pers. Med. 2022, 12(8), 1251; https://doi.org/10.3390/jpm12081251
Available online: https://www.mdpi.com/2075-4426/12/8/1251
Cited by 11+ | Viewed by 2265+

15. “Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease”
by Laura Valenzuela-Vallejo, Despina Sanoudou and Christos S. Mantzoros
J. Pers. Med. 2023, 13(5), 830; https://doi.org/10.3390/jpm13050830
Available online: https://www.mdpi.com/2075-4426/13/5/830
Cited by 10+ | Viewed by 2625+

To read more relevant papers, subscribe to JPM at https://www.mdpi.com/journal/jpm/toc-alert.

JPM Editorial Office

15 July 2024
Journal of Personalized Medicine | Big Reviews Project 2024

We invite you to participate in the Big Reviews Project 2024 of the Journal of Personalized Medicine (JPM, ISSN: 2075-4426).

The Big Review Project aims to commission comprehensive review papers co-authored by at least 3 recognized experts with multiple affiliation units (at least 3 units) to increase our portfolio of influential reviews.

Requirements for Big Reviews:

  1. Author Requirements
  • Leading authors should be senior Editorial Board Members and the first author to complete the Big Review. You may have a PostDoc or Ph.D. student in their final year assisting you (Ph.D. obtained or at least 3 publications);
  • The authors should be from two continents, with at least three affiliations, and at least two authors should be as senior as the journal's Editorial Board Members.
  1. Scope of Big Reviews

Authors can submit their Big Review to the corresponding Section based on their research focus. For detailed information on each Section, please click https://www.mdpi.com/journal/jpm/sections. If you are interested, please contact the Editorial Office for consultation as soon as possible.

In addition, we have some recommended hot topics for your reference:

  • Multi-omics analysis in cancer;
  • Pharmacogenomics in human disease;
  • Macrophage polarization in inflammatory diseases;
  • Vaccinomics;
  • Cancer, autophagy and apoptosis;
  • Tumor microenvironment;
  • Radiomics and radiogenomics;
  • Artificial intelligence in diagnostics and/or therapeutics in personalized medicine;
  • The tumor ecosystem: cellular interactions and therapeutic opportunities;
  • Bioinformatics for clinical applications in precision medicine;
  • Reconstructive microsurgery;
  • Sex hormones and gender in disease mechanisms;
  • lncRNAs in cancer;
  • Outcomes after critical illness.
  1. Word Count
    Big Reviews are expected to be a minimum of 6000 words.
  1. Benefits for authors
    4.1 The lead (invited) author will receive a travel grant of CHF 500. The travel grant will be granted to the lead author when attending a conference and promoting MDPI and the published Big Review to your colleagues.
    4.2 Other collaborators will receive a waiver for one submission to JPM. The other authors of Big Reviews, including non-leading authors, can enjoy one waiver for their other full research article or comprehensive review.
    4.3 Authors will receive a PDF booklet containing a selection of comprehensive reviews, which are published in the Journal of Personalized Medicine.
    4.4 All collaborators will be invited to join the journal’s physical meeting and online meeting. We will invite all Big Review authors to participate in journal-related theme meetings to provide you with a communication platform for interaction with outstanding Editorial Board Members.

Submission Guidelines:

  • Manuscripts should be submitted online through the Journal of Personalized Medicine portal (https://www.mdpi.com/journal/jpm);
  • Authors are encouraged to follow the journal's guidelines for formatting and referencing;
  • All submissions will undergo a rigorous peer review process to ensure the highest quality and relevance to the Special Issue.

Submission Deadline: 31 December 2024.

For more details or inquiries, please contact the Editorial Office.

JPM Editorial Office

12 July 2024
MDPI Webinar | World Hepatitis Day 2024, 29 July 2024


MDPI invites all experts recognized in their fields to attend the MDPI World Hepatitis Day Webinar 2024. Inspired by the collaborative spirit of World Hepatitis Day, this webinar aims to raise awareness about hepatitis and promote the development of innovative strategies to combat it. By engaging experts and the public, the webinar seeks to drive advancements and highlight the importance of collective efforts in scientific research and innovation.

We are looking forward to seeing you at the MDPI World Hepatitis Day Webinar 2024.

Title: MDPI World Hepatitis Day Webinar 2024
Date:
29 July 2024
Time:
15:00–17:00 (CEST) | 21:00–23:00 (CST Asia)
More Information: 
https://sciforum.net/event/WHD2024

This is a free webinar. After registration, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.

Unable to attend? Register anyway and we will let you know when the recording is available for viewing.

Register for free:

Program:

Speaker/Presentation

Time in CEST

Time in CST Asia

Host
Introduction

15:00–15:10

21:00–21:10

Assoc. Prof. Yee-Joo Tan
Delineating the roles of Hepatitis B viral proteins in mediating viral replication and pathogenesis

15:10–15:40

21:10–21:40

Dr. Giuseppe Colucci
WHO call for eradicating hepatitis C and B: micro elimination strategies, initial results and open issues

15:40–16:10

21:40–22:10

Prof. Dr. Chia-Yen Dai
Elimination of Hepatitis C: Last Mile

16:10–16:40

22:10-22:40

Q&A Session

16:40–16:50

22:40–22:50

Host
Closing of Webinar

16:50–17:00

22:50–23:00

Relevant Special Issues:

Animals
Diseases of the Small and Large Intestine, Liver and Pancreas in Small Animals: Second Edition
Edited by Dr. Alessio Pierini and Dr. Eleonora Gori
Deadline for submission: 20 December 2024

Metabolic Disorders of Poultry
Edited by Dr. Victoria Anthony Uyanga and Dr. Felix Kwame Amevor
Deadline for submission: 28 February 2025

Cancers
Hepatitis Viruses and Cancer
Edited by Prof. Dr. John Koskinas and Dr. Urania Georgopoulou
Deadline for submission: 1 November 2024

Cells
Interdisciplinary Approaches to Studying Human Liver Biology and Promoting Organ Regeneration: Understanding the Curse of Prometheus
Edited by Prof. Dr. David C. Hay, Dr. Matthew Sinton and Alvile Kasarinaite
Deadline for submission: N.A.

Children
Old and New Therapeutic Strategies in Children with Liver Disease
Edited by Dr. Raffaele Iorio and Dr. Fabiola Di Dato
Deadline for submission: 30 September 2024

Diagnostics
Diagnosis, Management, and Prognosis of Liver Disease and Its Syndromes
Edited by Prof. Dr. Chien Hao Huang
Deadline for submission: 31 August 2024

Diagnostic and Prognostic Markers in Liver Diseases
Edited by Dr. Dávid Tornai
Deadline for submission: 31 October 2024

Diagnosis of Liver Disease
Edited by Dr. Sung-Eun Kim
Deadline for submission: 31 December 2024

Gastroenterology Insights
Novelties in Diagnostics and Therapeutics in Hepatology: 2nd Edition
Edited by Dr. Giovanni Marasco and Dr. Matteo Renzulli
Deadline for submission: 31 December 2024

Journal of Personalized Medicine
Chronic Liver Disease: New Targets and New Mechanisms
Edited by Dr. Theodoros Androutsakos
Deadline for submission: 20 February 2025

Livers
Liver Fibrosis: Mechanisms, Targets, Assessment and Treatment
Edited by Prof. Dr. Ralf Weiskirchen and Prof. Dr. Tilman Sauerbruch
Deadline for submission: 20 December 2024

Medicina
Editorial Board Members’ Collection Series: Gastrointestinal and Hepatic Diseases
Edited by Prof. Dr. Ludovico Abenavoli and Dr. Marcello Candelli
Deadline for submission: 24 December 2024

Advances in Liver Surgery
Edited by Prof. Dr. Jai Young Cho
Deadline for submission: 24 December 2024

Novelties in Chronic Liver Diseases
Edited by Prof. Dr. Ludovico Abenavoli
Deadline for submission: 30 September 2024

Metabolites
Research on Pharmacotherapy of Metabolic-Associated Fatty Liver Disease
Edited by Dr. Aleksandra Bołdys
Deadline for submission: 30 September 2024

Metabolic Syndrome and Non-alcoholic Liver Disease
Edited by Prof. Dr. Mircea-Catalin Fortofoiu, and Dr. Luigi Boccuto
Deadline for submission: 20 October 2024

Liver Injury and Regeneration—Metabolic Research
Edited by Dr. Miguel Suárez Matías
Deadline for submission: 31 December 2024

Microorganisms
Hepatitis B Virus Infection and Vaccine
Edited by Dr. Nishi N. Prabdial-Sing
Deadline for submission: 15 December 2024

Nutrients
Metabolic-Dysfunction-Associated Steatotic Liver Disease at the Forefront: Confronting Nutritional Obstacles in Advanced Chronic Liver Disease and Portal Hypertension
Edited by Dr. Angelo Armandi and Dr. Federico Ravaioli
Deadline for submission: 15 October 2024

Prevention and Treatment of Liver Diseases by Dietary Habits and Lifestyle
Dr. Marica Cariello and Dr. Raffaella Maria Gadaleta
Deadline for submission: 15 December 2024

Managing Nonalcoholic Fatty Liver Disease with Nutrition
Edited by Dr. Nobuyuki Toshikuni
Deadline for submission: 25 December 2024

Pathogens
Zoonotic Hepatitis E Virus: A Focus on Animals, Food and Environment
Edited by Prof. Dr. Barbara Di Martino, Dr. Federica Di Profio and Dr. Andrea Palombieri  
Deadline for submission: 10 October 2024

Vaccines
Vaccines and Vaccination: HIV, Hepatitis Viruses, and HPV
Edited by Dr. Ivan Schietroma and Dr. Sonia Moretti
Deadline for submission: 28 February 2025

Vaccination and Treatments against Viral Hepatitis: Achievements, Challenges and Perspectives
Edited by Dr. Bárbara Vieira Do Lago and Dr. Vinicius M. Mello
Deadline for submission: 15 March 2025

10 July 2024
MDPI's Newly Launched Journals in June 2024

Five new journals covering multiple subjects have launched their inaugural issue in June 2024. We are excited to be able to share with you the newest research rooted in the value of open access.

We would like to express our deepest appreciation to all the Editorial Board Members and each journal will ensure its high-quality output using excellent editorial and rigorous peer review processes, to ensure that the articles achieve high impact and visibility.

Please feel free to browse and discover more about the new journals below.

Journal

Founding Editor-in-Chief

Journal Topics (Selected)

Anesthesia Research Logo

Prof. Dr. Marco Ranucci, IRCCS Policlinico San Donato, Italy
| Editorial | view inaugural issue

anaesthetic medications; blood and fluid management; pain management; critical care; critical illness | view journal scope | submit an article

Complications Logo

Dr. Giovanni E. Cacciamani, University of Southern California, USA
| Editorial | view inaugural issue

surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article

Laboratories Logo

Prof. Dr.  Gassan Hodaifa, Universidad Pablo de Olavide, Spain
| Editorial | view inaugural issue

laboratory management; laboratory safety; protective equipment; laboratory problems and challenges; laboratory Innovation | view journal scope | submit an article

Pets Logo

Prof. Dr. Jan S. Suchodolski, Texas A&M University, USA
| Editorial | view inaugural issue

companion animals health and disease; veterinary care and nutrition; genetics and genomics; behavior and welfare; human-animal relations | view journal scope | submit an article

Real Estate Logo

Prof. Dr. Pierfrancesco De Paola, University of Naples Federico II, Italy
| Editorial | view inaugural issue

real estate appraisal; economic and financial valuation of real estate projects; sustainable real estate; housing and urban economics | view journal scope | submit an article

We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com) if you would like to create more new journals.

30 June 2024
Journal of Personalized Medicine | Top 10 Cited Papers in 2022–2023 in the Section “Personalized Therapy and Drug Delivery”


We are pleased to invite you to read the top 10 cited papers in 2022 and 2023 in the Journal of Personalized Medicine (JPM, ISSN: 2075-4426) in the Section “Personalized Therapy and Drug Delivery”. The list of papers is as follows.

1. “Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials”
by Sudarshawn Damodharan, Montserrat Lara-Velazquez, Brooke Carmen Williamsen, Jeffrey Helgager and Mahua Dey
J. Pers. Med. 2022, 12(5), 840; https://doi.org/10.3390/jpm12050840
Available online: https://www.mdpi.com/2075-4426/12/5/840

2. “Should Neurosurgeons Try to Preserve Non-Traditional Brain Networks? A Systematic Review of the Neuroscientific Evidence”
by Nicholas B. Dadario and Michael E. Sughrue
J. Pers. Med. 2022, 12(4), 587; https://doi.org/10.3390/jpm12040587
Available online: https://www.mdpi.com/2075-4426/12/4/587

3. “Enhanced Permeability and Retention Effect as a Ubiquitous and Epoch-Making Phenomenon for the Selective Drug Targeting of Solid Tumors”
by Waliul Islam, Takuro Niidome and Tomohiro Sawa
J. Pers. Med. 2022, 12(12), 1964; https://doi.org/10.3390/jpm12121964
Available online: https://www.mdpi.com/2075-4426/12/12/1964

4. “Thyroid Diseases and Breast Cancer”
by Enke Baldini, Augusto Lauro, Domenico Tripodi, Daniele Pironi, Maria Ida Amabile, Iulia Catalina Ferent, Eleonora Lori, Federica Gagliardi, Maria Irene Bellini, Flavio Forte et al.
J. Pers. Med. 2022, 12(2), 156; https://doi.org/10.3390/jpm12020156
Available online: https://www.mdpi.com/2075-4426/12/2/156

5. “Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches”
by Valeria Conti, Graziamaria Corbi, Francesco Sabbatino, Domenico De Pascale, Carmine Sellitto, Berenice Stefanelli, Nicola Bertini, Matteo De Simone, Luigi Liguori, Ilenia Di Paola et al.
J. Pers. Med. 2023, 13(2), 334; https://doi.org/10.3390/jpm13020334
Available online: https://www.mdpi.com/2075-4426/13/2/334

6. “Advancing Patient Care: How Artificial Intelligence Is Transforming Healthcare”
by Diana Gina Poalelungi, Carmina Liana Musat, Ana Fulga, Marius Neagu, Anca Iulia Neagu, Alin Ionut Piraianu and Iuliu Fulga
J. Pers. Med. 2023, 13(8), 1214; https://doi.org/10.3390/jpm13081214
Available online: https://www.mdpi.com/2075-4426/13/8/1214

7. “The Effect of Meditation, Mindfulness, and Yoga in Patients with Rheumatoid Arthritis”
by Laura Slagter, Koen Demyttenaere, Patrick Verschueren and Diederik De Cock
J. Pers. Med. 2022, 12(11), 1905; https://doi.org/10.3390/jpm12111905
Available online: https://www.mdpi.com/2075-4426/12/11/1905

8. “Diagnostic Challenge of Invasive Lobular Carcinoma of the Breast: What Is the News? Breast Magnetic Resonance Imaging and Emerging Role of Contrast-Enhanced Spectral Mammography”
by Melania Costantini, Rino Aldo Montella, Maria Paola Fadda, Vincenzo Tondolo, Gianluca Franceschini, Sonia Bove, Giorgia Garganese and Pierluigi Maria Rinaldi
J. Pers. Med. 2022, 12(6), 867; https://doi.org/10.3390/jpm12060867
Available online: https://www.mdpi.com/2075-4426/12/6/867

9. “Application of Artificial Intelligence Techniques to Predict Risk of Recurrence of Breast Cancer: A Systematic Review”
by Claudia Mazo, Claudia Aura, Arman Rahman, William M. Gallagher and Catherine Mooney
J. Pers. Med. 2022, 12(9), 1496; https://doi.org/10.3390/jpm12091496
Available online: https://www.mdpi.com/2075-4426/12/9/1496

10. “Breast Reconstruction by Exclusive Lipofilling after Total Mastectomy for Breast Cancer: Description of the Technique and Evaluation of Quality of Life”
by Alexandre Piffer, Gabrielle Aubry, Claudio Cannistra, Nathalie Popescu, Maryam Nikpayam, Martin Koskas, Catherine Uzan, Jean-Christophe Bichet and Geoffroy Canlorbe
J. Pers. Med. 2022, 12(2), 153; https://doi.org/10.3390/jpm12020153
Available online: https://www.mdpi.com/2075-4426/12/2/153

Back to TopTop